Qiagen N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)

https://www.qiagen.com

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. *

	Start	1997-01-01 existent
	Group	Qiagen (Group)
	Predecessor	Diagen
	Industry	sample preparation (technology)
	Industry 2	molecular diagnostics
	Person	Bernard, Thierry (Qiagen 201502– SVP Molecular Dx business area before bioMérieux Corp VP Commcercial Operations)
	Person 2	Sackers, Roland (Qiagen 200408 CFO)

	Region	Venlo
	Country	Netherlands
	Street	50 Spoorstraat
	City	5911 KJ Venlo
		Address record changed: 2020-12-02

Basic data	Employees	G: 5,001 to 10,000 (2022-12-31)
	Currency	USD
	Annual sales	2,141,518,000 (net sales, consolidated (2022) 2022-12-31)
	Profit	423,211,000 (2022-12-31)
	Cash	730,669,000 (2022-12-31)

		* Document for »About Section«:

		Record changed: 2024-09-22